Functional Drug Profiling Identifies Targeted Leukemia Therapies Where Genomic Sequencing Falls Short
Direct ex vivo drug sensitivity testing of primary leukemia cells identifies actionable therapeutic vulnerabilities that conventional genomic profiling frequently overlooks.

